Swiss stocks stocks turned lower Friday, edging into negative territory for a third straight session amid renewed concerns about the global economy.
The benchmark SMI was down 0.48 percent to 6,219.36. The SLI was down 0.49 percent to 951.30. The SPI slipped 0.40 percent to 5,699.01.
Drug maker Roche was down 1.3 percent.
Sanofi lost an appeal against Roche's unit Genentech and U.S. biotech Biogen Idec over two top-selling cancer treatments, Rituxan and Avastin.
Credit Suisse says it is cooperating with a probe into whether some investment banks manipulated Libor. Shares were down 0.2 percent.
Credit Suisse CEO Brady Dougan in 2011 had his pay cut 69 percent from 2010, reflecting the firm's financial performance and fall in share price.
Richemont SA said it will end its share buy-back program. The stock slipped 2 percent in early dealing.
For comments and feedback contact: editorial@rttnews.com
Market Analysis
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.